• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Virta Health touts triple-digit growth with insurers as market shifts toward diabetes reversal

December 14, 2021 By Sean Whooley

Virta HealthVirta Health announced today that it now works with more than 20 national and regional health plans, marking triple-digit growth.

San Francisco-based Virta Health, which develops type 2 diabetes reversal technology, has now grown 133% year-over-year with large insurer customers that now offer its treatment to self-funded employer groups, including Humana and Providence Health Plan.

The company said in a news release that heightened demand for its diabetes reversal technology goes hand-in-hand with an industry-wide shift toward reversal as a method to treat diabetes. Virta said an analysis with methodology validated by the actuarial firm Milliman demonstrated payer savings of $425 per Virta patient per month, or $10,000 over the first two years.

Additionally, a consensus report from the American Diabetes Association, the Endocrine Society, the European Association for the Study of Diabetes, and Diabetes UK defined diabetes reversal for the first time while refining remission criteria, recognizing the apparent transition to diabetes reversal technology in the market.

“The tide is turning towards disease reversal as the primary goal for type 2 diabetes treatment,” Virta CEO & Co-Founder Sami Inkinen said in the release. “Our accelerating health plan growth affirms this shift, as payers race to cut costs while helping patients transform their health.”

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: Virta Health

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS